利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.02 秒)

    Stent and stent delivery system with improved deliverability
    1.
    发明授权
    Stent and stent delivery system with improved deliverability 有权

    公开(公告)号：US11369498B2

    公开(公告)日：2022-06-28

    申请号：US13014632

    申请日：2011-01-26

    申请人： James B. McClain ,  Douglas Taylor ,  David Enscore

    发明人： James B. McClain ,  Douglas Taylor ,  David Enscore

    IPC分类号： A61F2/958 ,  A61F2/00 ,  A61F2/82

    摘要： Stent delivery systems having improved deliverability comprising an elongate member having an inflation lumen and a guidewire lumen therein; a balloon having an interior that is in fluid communication with the inflation lumen; and a stent comprising a coating mounted on the balloon. Methods for making stent delivery systems having improved deliverability. Methods for delivering two stent delivery systems concurrently through a guiding catheter, each stent delivery system comprising elongate member having an inflation lumen and a guidewire lumen therein, a balloon having an interior that is in fluid communication with the inflation lumen, and a stent comprising a coating mounted on the balloon. Stent coatings may comprise a pharmaceutical agent at least a portion of which is in crystalline form.

    STENT AND STENT DELIVERY SYSTEM WITH IMPROVED DELIVERABILITY
    2.
    发明申请
    STENT AND STENT DELIVERY SYSTEM WITH IMPROVED DELIVERABILITY 审中-公开
    具有改进的可交付性的STENT和STENT交付系统

    公开(公告)号：US20110190864A1

    公开(公告)日：2011-08-04

    申请号：US13014632

    申请日：2011-01-26

    申请人： James B. McClain ,  Douglas Taylor ,  David Enscore

    发明人： James B. McClain ,  Douglas Taylor ,  David Enscore

    IPC分类号： A61F2/84 ,  A61F2/82

    CPC分类号： A61F2/958 ,  A61F2/0077 ,  A61F2002/826 ,  A61F2250/003

    摘要： Stent delivery systems having improved deliverability comprising an elongate member having an inflation lumen and a guidewire lumen therein; a balloon having an interior that is in fluid communication with the inflation lumen; and a stent comprising a coating mounted on the balloon. Methods for making stent delivery systems having improved deliverability. Methods for delivering two stent delivery systems concurrently through a guiding catheter, each stent delivery system comprising elongate member having an inflation lumen and a guidewire lumen therein, a balloon having an interior that is in fluid communication with the inflation lumen, and a stent comprising a coating mounted on the balloon. Stent coatings may comprise a pharmaceutical agent at least a portion of which is in crystalline form.

    摘要翻译： 具有改善的输送能力的支架输送系统包括具有充气腔和其中的导丝腔的细长构件; 具有与膨胀腔流体连通的内部的气囊; 以及支架，其包括安装在气囊上的涂层。 用于制备具有改善的输送性的支架输送系统的方法。 用于通过引导导管同时递送两个支架输送系统的方法，每个支架输送系统包括具有充气腔和其中的导丝腔的细长构件，具有与充气腔流体连通的内部的球囊，以及支架， 涂层安装在气球上。 支架涂层可以包含至少一部分为结晶形式的药剂。

    Permeant delivery system and methods for use thereof
    3.
    发明申请
    Permeant delivery system and methods for use thereof 审中-公开
    渗透输送系统及其使用方法

    公开(公告)号：US20070031495A1

    公开(公告)日：2007-02-08

    申请号：US11455899

    申请日：2006-06-19

    申请人： Jonathan Eppstein ,  David Enscore ,  Frank Tagliaferri ,  Gaurav Tolia ,  Shulun Chang ,  Alan Smith ,  Yogi Patel ,  Stuart McRae

    发明人： Jonathan Eppstein ,  David Enscore ,  Frank Tagliaferri ,  Gaurav Tolia ,  Shulun Chang ,  Alan Smith ,  Yogi Patel ,  Stuart McRae

    IPC分类号： A61K9/24

    CPC分类号： A61K9/7053 ,  A61K9/0009

    摘要： Disclosed is a device for causing the transdermal flux of a per meant into a subject via at least one formed pathway through a skin layer of the subject. The device comprises a delivery reservoir comprising: i) a non-biodegradable matrix having a bottom surface and defining a plurality of conduits therein the matrix, at least a portion of the plurality of conduits being in communication with the bottom surface; and ii)an undissolved hydrophilic per meant disposed therein at least a portion of the plurality of conduits of the matrix, wherein the hydrophilic per meant can come in contact with subcutaneous fluid from the subject when the bottom surface of the matrix is positioned in fluid communication with the at least one formed pathway. Also disclosed are systems and methods for causing the transdermal flux of a per meant into a subject via at least one formed pathway through a skin layer of the subject.

    摘要翻译： 公开了一种用于通过穿过受试者的皮肤层的至少一个形成的途径使每个意图的经皮通量引入受试者的装置。 所述装置包括递送贮存器，其包括：i）具有底表面并且在其中限定所述基质中的多个导管的不可生物降解的基质，所述多个导管的至少一部分与所述底表面连通; 和ii）未溶解的亲水剂，其中每个意图在其中设置多个基质管道的至少一部分，其中，当基质的底表面位于流体连通中时，每个意图的亲水剂可以与来自受试者的皮下流体接触 与至少一个形成的途径。 还公开了用于通过穿过受试者的皮肤层的至少一个形成的途径使每个意图的经皮通量引入受试者的系统和方法。

    Polymeric drug delivery system for hydrophobic drugs
    5.
    发明申请
    Polymeric drug delivery system for hydrophobic drugs 审中-公开
    用于疏水药物的聚合物药物递送系统

    公开(公告)号：US20050249799A1

    公开(公告)日：2005-11-10

    申请号：US11072098

    申请日：2005-03-03

    申请人： Jules Jacob ,  Michael Bassett ,  Marcus Schestopol ,  Edith Mathlowitz ,  Avinash Nangia ,  Bennett Carter ,  Peyman Moslemy ,  Ze'ev Shaked ,  David Enscore ,  Courtney Sikes

    发明人： Jules Jacob ,  Michael Bassett ,  Marcus Schestopol ,  Edith Mathlowitz ,  Avinash Nangia ,  Bennett Carter ,  Peyman Moslemy ,  Ze'ev Shaked ,  David Enscore ,  Courtney Sikes

    IPC分类号： A61K9/00 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/24 ,  A61K9/28 ,  A61K9/48

    CPC分类号： A61K9/209 ,  A61K9/0065 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1647 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2086 ,  A61K9/2853

    摘要： An oral delivery system for Class II drugs that have low oral bioavailability due to their insolubility in water and slow dissolution kinetics and method for making such a drug delivery system are disclosed herein. The formulation may be a controlled release or immediate release formulation. The immediate release formulation contains a Class II drug, together with a hydrophobic polymer, preferably a bioadhesive polymer. In one embodiment, the drug and polymer are co-dissolved in a common solvent. The solution is formed into small solid particles by any convenient method, particularly by spray drying. The resulting particles contain drug dispersed as small particles in a polymeric matrix. The particles are stable against aggregation, and can be put into capsules or tableted for administration. The controlled release formulations contain a BCS Class II drug and a bioadhesive polymer. The controlled release formulations may be in the form of a tablet, capsules, mini-tab, microparticulate, or osmotic pump. Enhancement of oral uptake of the drug from use of bioadhesive polymers occurs through (1) increased dissolution kinetics due to stable micronization of the drug, (2) rapid release of the drug from the polymer in the GI tract; and (3) prolonged GI transit due to bioadhesive properties of the polymers. The combination of these effects allows the preparation of a compact, stable dosage form suitable for oral administration of many class II drugs.

    摘要翻译： 本文公开了由于其在水中的不溶性和缓慢的溶解动力学以及制备这种药物递送系统的方法而具有低口服生物利用度的II类药物的口服递送系统。 制剂可以是控释或即时释放制剂。 立即释放制剂含有II类药物，以及疏水性聚合物，优选生物粘附性聚合物。 在一个实施方案中，将药物和聚合物共溶于常用溶剂。 通过任何方便的方法，特别是通过喷雾干燥，将溶液形成小的固体颗粒。 所得到的颗粒含有作为小颗粒分散在聚合物基质中的药物。 颗粒对聚集是稳定的，并且可以放入胶囊或压片以供给药。 控释制剂含有BCS II类药物和生物粘附性聚合物。 控制释放制剂可以是片剂，胶囊，迷你片，微粒或渗透泵的形式。 通过（1）由于药物的稳定的微粉化引起的溶出动力学增加，（2）药物从胃肠道中的聚合物快速释放，增加了使用生物粘附性聚合物对药物的口服摄取。 和（3）由于聚合物的生物粘合性质而延长GI运输。 这些作用的组合允许制备适于口服多种II类药物的紧凑，稳定的剂型。

    Bioadhesive drug delivery system with enhanced gastric retention
    6.
    发明申请
    Bioadhesive drug delivery system with enhanced gastric retention 审中-公开
    生物粘附药物递送系统具有增强的胃滞留

    公开(公告)号：US20050064027A1

    公开(公告)日：2005-03-24

    申请号：US10498661

    申请日：2002-12-13

    申请人： Jules Jacob ,  Edith Mathiowitz ,  David Enscore ,  Marcus Schestopol

    发明人： Jules Jacob ,  Edith Mathiowitz ,  David Enscore ,  Marcus Schestopol

    IPC分类号： A61K9/30 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K9/50 ,  A61K9/52 ,  A61K31/522 ,  A61K45/00 ,  A61K47/04 ,  A61K47/36 ,  A61K47/42 ,  A61P31/12 ,  A61P31/20 ,  A61P33/00 ,  A61P35/00

    CPC分类号： A61K9/0065 ,  A61K9/501 ,  A61K9/5026 ,  A61K9/5031 ,  A61K9/5073

    摘要： Bioadhesive macrosphere delivery systems (“BDDS”) having prolonged gastric retention time due to bioadhesion rather than physical density or size are described. In general, the macrospheres have diameters that are greater than 200 microns, more preferably greater than 500 microns. The bioadhesive macrospheres are released in the stomach where they reside in close proximity to the gastric mucosa for a prolonged period of time. Increased residence of BDDS in the upper GI can lead to increased systemic absorption of drug in the preferred site of systemic absorption, namely the upper GI tract (upper to mid-jejunum). The BDDS may be engineered either as a capsule with drug delivery controlled by a diffusion-limited membrane or degradable shell, or as a solid matrix system with drug delivery controlled by a combination of diffusion and polymer degradation kinetics.

    摘要翻译： 描述了由于生物粘附而不是物理密度或大小而具有延长的胃停留时间的生物粘附大球传递系统（“BDDS”）。 通常，大球的直径大于200微米，更优选大于500微米。 生物粘附的大球在胃中被释放，其中它们靠近胃粘膜存在一段较长的时间。 增加BDDS在上GI中的居住可导致药物在全身吸收的优选部位，即上胃肠道上（上至中空）中的全身吸收增加。 BDDS可以被设计为具有由扩散限制膜或可降解壳控制的药物递送的胶囊，或者作为具有由扩散和聚合物降解动力学的组合控制的药物递送的固体基质体系。